HOME >> BIOLOGY >> NEWS
Most clones doomed from the start, according to Temple University embryologist

Until scientists can improve the early development of cloned embryos, cloning will remain marginally successful, according to research presented today at the American Association for the Advancement of Science (AAAS). Currently, only 1-5 percent of cloned embryos succeed, and many that do succeed are unhealthy.

Keith Latham, Ph.D., Associate Professor of Biochemistry at Temple University School of Medicine, presented the research during the symposium, "Cloning Controversies: Ethics, Science and Society." Latham's presentation, "Somatic Cell-Like Features of Cloned Embryos," highlighted the differences that persist between a normal embryo and a cloned embryo and stand in the way of cloning success.

Contributing to the poor success is the inefficiency and slow rate of reprogramming. Reprogramming is the process whereby cloned embryo genes are turned off and normal embryo genes are turned on, allowing a cloned embryo to develop normally. For some reason, most cloned embryos are unable to make this transformation. Consequently, cloned embryos develop and behave as a hybrid somewhere between an embryo and the adult organism from which it has been cloned.

"Until we learn how to improve the reprogramming of cloned embryos and how to help them transition into a normal, healthy embryo, cloning will remain marginally successful," said Latham.

Latham's research portfolio is focused on reproduction and development at the molecular level. He is currently running four major research projects, all funded by the National Institutes of Health.


'"/>

Contact: Eryn Jelesiewicz
eryn.jelesiewicz@temple.edu
215-707-0730
Temple University
16-Feb-2004


Page: 1

Related biology news :

1. Advance warning of storms and cyclones with new technique
2. Texas A&M clones first cat
3. New study shows normal-looking clones may be abnormal
4. The silence of the clones: new link between DNA replication and silent chromosome architecture
5. Dyslexics not doomed to life of reading difficulties
6. Portrait of a doomed Sea
7. The future of HIV therapeutics is brightening, according to Gladstone Institutes Director
8. Mitochondria in spinal cords is ALS target according to UCSD medical researchers
9. Espionage may have driven the evolution of bee language according to UCSD-led study in Brazil
10. Chicken litter harbors agents that generate antibiotic multi-resistance, according to UGA study
11. Governing commons still a struggle, but fight not without hope, according to new report

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/28/2020)... ... June 25, 2020 , ... ... biopharmaceutical R&D, today announced that it has entered into a multi-year contract ... (Multiclonics®), to support their translational and clinical research strategy to discover and ...
(Date:6/25/2020)... ... June 24, 2020 , ... ... software and software-driven clinical data services that accelerate drug development, is collaborating with ... an XPO1 inhibitor, in hospitalized patients with severe COVID-19. This is the first ...
(Date:6/23/2020)... , ... June 23, 2020 , ... ... sustainable healthcare, and Renovagen Ltd, a UK supplier and manufacturer of innovative portable ... support testing operations in the fight against the COVID-19 pandemic in Zambia. , ...
Breaking Biology News(10 mins):
(Date:5/28/2020)... (PRWEB) , ... May 28, 2020 , ... The ... and security leaders as the 2020 winners of the Women in Biometrics Awards ... sponsors IDEMIA , Biometric Update and the SIA Women in ...
(Date:5/21/2020)... ... , ... Threats to intellectual property, political pressure to lower ... wisdom that says the coronavirus pandemic will generally benefit biopharmaceutical companies, a new ... commercially weaker, dealing with delays in new product launches and with fewer resources ...
(Date:5/21/2020)... ... ... Eaton Square is pleased to announce its growth on the East Coast of ... strategy and M&A advisory firm. , This is an important step for Eaton Square ... healthcare innovators with capital and investors. , Popper and Company, founded in 2003 by ...
(Date:5/15/2020)... (PRWEB) , ... May 14, ... ... supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks and hMSC ... to enable streamlined and multi-format collection of hMSC-derived extracellular vesicles (EVs). RoosterCollect™-EV-CC ...
Breaking Biology Technology:
Cached News: